ArticleJournal of thrombosis and haemostasis : JTH2021
Venous thromboembolism incidence among patients recommended for pharmacologic thromboembolism prophylaxis after cesarean delivery in selected guidelines.
Article in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Single Center Implementation of a Postpartum Pharmacologic Thromboprophylaxis Protocol.American journal of perinatology · 2026Article
- Postoperative venous thromboembolism following cesarean delivery: prevalence, pathophysiology, diagnosis, treatment, and prevention.American journal of obstetrics and gynecology · 2026Review
- Racial and ethnic disparities in eligibility for postpartum venous thromboembolism prophylaxis in the United States.Journal of thrombosis and haemostasis : JTH · 2024Article
- Projected impact of guidelines on incidence of venous thromboembolism after cesarean delivery in the United States.Journal of thrombosis and haemostasis : JTH · 2023Article
- High rates of venous thromboembolism among deliveries complicated by cancer.Journal of thrombosis and haemostasis : JTH · 2023Article
- Development and validation of a facile rapid assessment scale for perinatal venous thromboembolism in puerperium in Chinese women.BMC pregnancy and childbirth · 2023Article
- Cost-effectiveness of mechanical thromboprophylaxis for cesarean deliveries in Brazil.PloS one · 2023Article
- For better care we need better data: towards a national obstetrics registry.American journal of obstetrics & gynecology MFM · 2023Review
- Preventing Postpartum Venous Thromboembolism in 2022: A Narrative Review.Frontiers in cardiovascular medicine · 2022Review
- Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation.Hematology. American Society of Hematology. Education Program · 2021Article
- Postpartum Heparin Thromboprophylaxis: More Harm Than Good.Obstetrics and gynecology · 2021Article
- Pharmacist-Led Discharge Counseling and Adherence to Postpartum Venous Thromboembolism Prophylaxis: A Pre-Post Observational Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMultiple guidelines regarding risk stratification for venous thromboembolism (VTE) incidence following cesarean delivery have been promulgated.
objectiveTo estimate the percentage of cesarean delivery patients for which pharmacologic VTE would be recommended and subsequent incidence of VTE, based on several guidelines. PATIENTS/
methodsThis retrospective cohort study used data from the Nationwide Readmissions Database from October 2015 through December 2017. Diagnosis and procedure codes were used to identify patients undergoing cesarean delivery, incidence of VTE, and risk factors used to stratify risk in the existing guidelines. Time-to-event analysis was used to analyze data, stratified by risk categorization in 2011 American College of Obstetricians and Gynecologists (ACOG), 2012 American College of Chest Physicians (ACCP), 2015 Royal College of Obstetricians and Gynaecologists (RCOG), and 2018 American Society of Hematology (ASH) guidelines. RESULTS/
conclusionsIn a cohort of 1 235 149 cesarean deliveries, VTE incidence was 2.1 per 1000 deliveries at 330 days following delivery (95% confidence interval: 2.0-2.2). Proportions of patients that would be recommended for pharmacologic prophylaxis ranged from 0.2% in 2018 ASH guidelines to 73.4% in 2015 RCOG criteria. Among groups considered at elevated risk for VTE for which pharmacologic prophylaxis would be recommended, VTE incidence varied from 35.2 per 1000 deliveries based on 2018 ASH criteria to 2.5 per 1000 in 2015 RCOG criteria. In a large cohort of cesarean deliveries in the United States, application of different risk stratification guidelines identified widely different proportions at risk of VTE following delivery, with implications for being categorized as having elevated risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.